Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

   published on

   01.02.2019

   Document type

   PDF document, 138 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 138 kB, EN, not accessible)
2. Dossier assessment

   Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

   published on

   01.02.2019

   Document type

   PDF document, 1 MB, DE, not accessible

   Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Additional information

Project details

Project no.

A18-75

Commission

Commission awarded on 30.10.2018 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

1. Dossier assessment

   Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

   Project no.

   A20-93

   Last updated

   01.02.2021

   Status: Commission completed